Table 2. Cell-of-origin based therapy and outcome in diffuse large B-cell lymphoma.

Regimen [Reference]	DLBCL	Phase	Number	Stage	Response (ABC/non-GCB vs GCB)	Outcome (ABC/non-GCB vs GCB)
R-CHOP [23]	Untreated		233	II-IV		3-yr PFS: 40% vs 74%
DA-EPOCH-R [24]	Untreated	II	71	II-IV		5-yr PFS: 56% vs 79% 5-yr OS: 64% vs 84%
DA-EPOCH-R [25]	Untreated	II	69	II-IV		5-yr TTP: 67% vs 100% 5-yr EFS: 58% vs 94% 5-yr OS: 68% vs 94%
Bortezomib + DA-EPOCH [27]	Relapse/Refractory	II	27		ORR: 83% vs 13% CR: 42% vs 6%	median OS: 10.8 mon vs 3.4 mon
Lanalidomide [29]	Relapse/Refractory	Retrospective	40	I-IV	ORR: 52.9% vs 8.7% CR: 29.4% vs 4.3%	median PFS: 6.2 mon vs 1.7 mon median OS: 14 mon vs 13 mon
Lanalidomide + R-CHOP [31]	Untreated	II	32	II-IV	ORR: 88% vs 88% CR: 88% vs 81%	2-yr EFS: 74% vs 61% 2-yr PFS: 81% vs 71% 2-yr OS: 94% vs 88%
Lanalidomide + R-CHOP [30]	Untreated	II	64	II-IV		2-yr PFS: 60% vs 59% 2-yr OS: 83% vs 75%
Ibrutinib [25]	Relapse/Refractory	I/II	58		ORR: 37% vs 5% CR: 16% vs 0%	median PFS: 2.02 mon vs 1.31 mon median OS: 10.32 mon vs 3.35 mon
Ibrutinib + R-CHOP [34]	Untreated	Ib	11	Bulky I-IV	ORR: 100% vs 100% CR: 100% vs 71%

DLBCL, diffuse large B-cell lymphoma; ABC, activated B-cell like; GCB, germinal center B-cell like; yr, year; mon, months; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prodnisone; DA-EPOCH, dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide and predonisone; PFS, progression-free survival; OS, overall survival; TTP, time to progression survival; EFS, event-free survival; ORR, overall response rate; CR, complete response rate